Janssen Shows 35% Drop in Mortality with Prostate Cancer Drug

A final analysis of the Phase III TITAN study shows that Janssen’s ERLEADA® (apalutamide), when added to androgen deprivation therapy (ADT), significantly improved overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC) compared with placebo.